RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
RARX
Delisted
RARX was delisted on the 1st of April, 2020.
146 hedge funds and large institutions have $2.31B invested in Ra Pharmaceuticals, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 71 funds opening new positions, 29 increasing their positions, 36 reducing their positions, and 44 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
19% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 36
80% less call options, than puts
Call options by funds: $4.4M | Put options by funds: $22.1M
Holders
146
Holding in Top 10
5
Calls
$4.4M
Puts
$22.1M
Top Buyers
| 1 | +$99.3M | |
| 2 | +$89.5M | |
| 3 | +$86.3M | |
| 4 |
Citigroup
New York
|
+$79.5M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$55.8M |
Top Sellers
| 1 | -$190M | |
| 2 | -$53M | |
| 3 | -$51.8M | |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$33.4M |
| 5 |
First Manhattan
New York
|
-$32.5M |